BioSpace News Archive

This automated system provides a proven platform for unbiased isolation, evaluation, and selection of over a thousand single cells for downstream analyses, including NGS, backed by recent citations in the literature.

Results from the IIR support the findings of the investigator review per mRECIST, confirming lenvatinib demonstrated statistically significant and clinically meaningful improvements across all secondary efficacy endpoints.

Atreca announced today that Norman Michael Greenberg, Ph.D., Senior Vice President and Chief Scientific Officer, will deliver a presentation on the Company’s lead programs in immuno-oncology as part of the Immunotherapy Showcase during the 2018 Precision Medicine World Conference on Wednesday, January 24, 2018, at 1:45 PM PT in Mountain View, CA.

The offering is expected to close on or about January 23, 2018, subject to customary closing conditions.

The application is based on Phase II and III clinical trial contract milestones from leading biopharma companies and CROs.

E7046 is an orally administered, selective EP4 receptor antagonist discovered by Eisai’s U.S. Andover research facility.

Indivior today announced that it will release its full year 2017 results on February 15th at 7:00 a.m. London time (2:00 a.m. U.S. EST).

Under the collaboration, SII is entitled to manufacture and sell fully liquid wP and Salk based IPV based Hexavalent vaccine developed and commercialized by PBL.

OncLive, the leading digital provider of resources and information for oncology professionals, will host the State of the Science Summi: Genitourinary Cancers at the New York Marriott at the Brooklyn Bridge in Brooklyn, New York, on January 25 at 5:30 p.m.

Invacare announces that it will release its financial results for the fourth quarter and year ended December 31, 2017, after the market closes on Wednesday, February 7, 2018.